Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot could help when arthritis drugs fail

NCT ID NCT06754462

Disease control Sponsor: Immunovant Sciences GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called IMVT-1402 in 120 adults with active, difficult-to-treat rheumatoid arthritis. Participants receive weekly injections of either the drug or a placebo. The goal is to see if the drug helps maintain symptom improvement over 28 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
IMVT-1402 (a drug given as a weekly injection under the skin)
What this could lead to
If it works, this could provide a new treatment option for people with hard-to-treat rheumatoid arthritis, helping them maintain symptom control.
What could go wrong
This is a mid-stage trial with only 120 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2025

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male and Female participants of age \>18 years will be enrolled. * Diagnosis of 'definite RA' according to the 2010 ACR/ European Alliance of Associations for Rheumatology (EULAR) Rheumatoid Arthritis Classification Criteria. * Greater than or equal to 6/68 in tender joint count (TJC) and ≥ 6/66 swollen joint count (SJC) at both Screening and Baseline visits. * C-reactive protein ≥ upper limit of normal (ULN) at Screening Visit. * Elevated immunoglobulin G (IgG) + ACPA at the Screening Visit. * Inadequate response to at least 2 classes of biologic/targeted synthetic disease-modifying antirheumatic drugs (DMARDs). Additional inclusion criteria are defined in the protocol. Exclusion Criteria: * Have received rituximab and experienced insufficient efficacy or loss of efficacy * History of any chronic inflammatory arthritis with onset prior to age 18 or history of acute inflammatory joint disease of different origin from RA. * Active malignancy or history of malignancy within 5 years prior to Screening Visit. * Medical history of primary immunodeficiency, T cell or humoral, including common variable immunodeficiency. * Used any nonimmunosuppressive fragment crystallizable (Fc)-based therapeutic protein (e.g., monoclonal antibody \[mAb\] or Fc-fusion protein) within 4 weeks prior to or at Screening Visit. * Used any anti-FcRn treatment within 2 months prior to or at Screening Visit or have a documented history of non-response to prior anti-FcRn treatment. Other, more specific exclusion criteria are defined in the protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Rheumatoid arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Rheumatoid arthritis

Contacts and locations

Locations

  • Site Number - 1000

    Duncansville, Pennsylvania, 16635, United States

  • Site Number - 1001

    Gainesville, Georgia, 30501, United States

  • Site Number - 1002

    Miami, Florida, 33143, United States

  • Site Number - 1004

    Charlotte, North Carolina, 28207, United States

  • Site Number - 1005

    Winter Park, Florida, 32789, United States

  • Site Number - 1006

    Cumberland, Maryland, 21502, United States

  • Site Number - 1007

    Hagerstown, Maryland, 21740, United States

  • Site Number - 1008

    Worcester, Massachusetts, 01605, United States

  • Site Number - 1010

    Summit, New Jersey, 07901, United States

  • Site Number - 1012

    Zephyrhills, Florida, 33542, United States

  • Site Number - 1013

    Tomball, Texas, 77375, United States

  • Site Number - 1014

    Mesquite, Texas, 75150, United States

  • Site Number - 1015

    Jupiter, Florida, 33458, United States

  • Site Number - 1016

    Jackson, Tennessee, 38305, United States

  • Site Number - 1017

    Colleyville, Texas, 76034, United States

  • Site Number - 1018

    Mesa, Arizona, 85210, United States

  • Site Number - 1019

    Sun City, Arizona, 85351, United States

  • Site Number - 1020

    Denver, Colorado, 80230, United States

  • Site Number - 1021

    Saint Clair Shores, Michigan, 48081, United States

  • Site Number - 1022

    Covina, California, 91722, United States

  • Site Number - 1023

    Whittier, California, 90602, United States

  • Site Number - 1024

    Temecula, California, 92592, United States

  • Site Number - 1025

    Tomball, Texas, 77377, United States

  • Site Number - 1026

    Memphis, Tennessee, 38119, United States

  • Site Number - 1027

    Plantation, Florida, 33324, United States

  • Site Number - 1028

    San Leandro, California, 94578, United States

  • Site Number - 1029

    Murfreesboro, Tennessee, 37128, United States

  • Site Number - 1030

    Kansas City, Missouri, 64151, United States

  • Site Number - 1031

    Rockville, Maryland, 20850, United States

  • Site Number - 1033

    Tujunga, California, 91042, United States

  • Site Number - 1034

    Chicago, Illinois, 60607, United States

  • Site Number - 1035

    Statesville, North Carolina, 28625, United States

  • Site Number - 1036

    Katy, Texas, 77494, United States

  • Site Number - 1037

    Allen, Texas, 75013, United States

  • Site Number - 3000

    Poznan, 61-397, Poland

  • Site Number - 3002

    Wroclaw, 53-673, Poland

  • Site Number - 3003

    Sochaczew, 96-500, Poland

  • Site Number - 3004

    Warsaw, 02-665, Poland

  • Site Number - 3005

    Bialystok, 15-879, Poland

  • Site Number - 3006

    Nadarzyn, 05-830, Poland

  • Site Number - 3007

    Elblag, 82-300, Poland

  • Site Number - 3008

    Poznan, 60-848, Poland

  • Site Number - 3009

    Lublin, 20-607, Poland

  • Site Number - 3200

    Zlín, 760 01, Czechia

  • Site Number - 3201

    Uherské Hradiště, 686 01, Czechia

  • Site Number - 3202

    Ostrava, 702 00, Czechia

  • Site Number - 3203

    Praha 2 Nove Mesto, 128 50, Czechia

  • Site Number - 3204

    Brno, 638 00, Czechia

  • Site Number - 5000

    San Miguel de Tucumán, 4000, Argentina

  • Site Number - 5001

    Buenos Aires, 1425, Argentina

  • Site Number - 5002

    Buenos Aires, C1118AAF, Argentina

  • Site Number - 5003

    Buenos Aires, 1417, Argentina

  • Site Number - 5005

    Buenos Aires, C1180AAX, Argentina

  • Site Number - 5600

    Sofia, 1336, Bulgaria

  • Site Number - 5601

    Sofia, 1680, Bulgaria

  • Site Number - 5602

    Plovdiv, 4004, Bulgaria

  • Site Number - 5603

    Plovdiv, 4000, Bulgaria

  • Site Number - 5604

    Rousse, 7000, Bulgaria

  • Site Number - 5605

    Plovdiv, 4002, Bulgaria

  • Site Number - 5606

    Sevlievo, 5400, Bulgaria

  • Site Number - 6500

    Hamburg, 20095, Germany

  • Site Number - 6501

    Ratingen, 40878, Germany

  • Site Number - 7000

    Edinburgh, EH4 2XU, United Kingdom

  • Site Number - 7001

    London, SE5 9RJ, United Kingdom

  • Site Number - 7003

    Wolverhampton, WV10 0QP, United Kingdom

  • Site Number - 7100

    Seville, 41009, Spain

  • Site Number - 7101

    Bilbao, 48013, Spain

  • Site Number - 7102

    Málaga, 29009, Spain

  • Site Number - 7104

    Barcelona, 08208, Spain

  • Site Number - 7500

    Brasov, 500283, Romania

  • Site Number - 7501

    Râmnicu Vâlcea, 240636, Romania

  • Site Number - 7502

    Bucharest, 020475, Romania

  • Site Number - 7550

    Hódmezővásárhely, 6800, Hungary

  • Site Number - 7551

    Székesfehérvár, 8000, Hungary

  • Site Number - 7552

    Veszprém, 8200, Hungary

  • Site Number - 7553

    Kecskemét, 6000, Hungary

  • Site Number - 7554

    Budapest, 1027, Hungary

  • Site Number - 7555

    Budapest, 1027, Hungary

  • Site Number - 8000

    Tbilisi, 0159, Georgia

  • Site Number - 8001

    Tbilisi, 0160, Georgia

  • Site Number - 8003

    Tbilisi, 0186, Georgia

  • Site Number -5004

    Buenos Aires, C1046, Argentina

  • Site Number -7002

    North Shields, NE29 8NH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.